Manhard Kimberly's Form 4 filing
Heron Therapeutics, Inc.HRTX · filed May 4, 2022
- Accession no.
- 0001209191-22-027232
- Filed
- May 4, 2022
- Trade date
- Apr 29-May 3, 2022
- Filing delay
- 5 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $7.16K. It was filed 5 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Manhard KimberlyCIK 0001202094 | Director, Officer (EVP, Drug Development) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 29, 2022 | Common Stock | JOtherAcquired | +1,504 | $3.84 | +$5,775.36 | 12,376 | Direct | |
| May 3, 2022 | Common Stock | SSaleDisposed | −1,504 | $4.76F3 | −$7,159.04 | 10,872 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The range of sales prices received was $4.695 to $4.835. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
Referenced by the price of 1 transaction in Table I.